Short-Term Efficacy and Safety of IL-17, IL-12/23, and IL-23 Inhibitors Brodalumab, Secukinumab, Ixekizumab, Ustekinumab, Guselkumab, Tildrakizumab, and Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials

BACKGROUND: The role of interleukin-12 (IL-12), interleukin-23 (IL-23), and interleukin-17 (IL-17) has been recognized in psoriasis pathogenesis, and new drugs targeting this axis have already been developed which may provide a new therapeutic approach for patients with moderate to severe psoriasis....

Descripción completa

Detalles Bibliográficos
Autores principales: Bai, Fan, Li, Gang Gang, Liu, Qingmin, Niu, Xinwu, Li, Ruilian, Ma, Huiqun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2019
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6754904/
https://www.ncbi.nlm.nih.gov/pubmed/31583255
http://dx.doi.org/10.1155/2019/2546161

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6754904/
https://www.ncbi.nlm.nih.gov/pubmed/31583255
http://dx.doi.org/10.1155/2019/2546161

Ejemplares similares